Exenatide: a GLP-1 receptor agonist as novel therapy for Type 2 diabetes mellitus. - Wikidata - wikimedia - TriplyDB

Exenatide: a GLP-1 receptor agonist as novel therapy for Type 2 diabetes mellitus.

Exenatide: a GLP-1 receptor agonist as novel therapy for Type 2 diabetes mellitus.

http://www.wikidata.org/entity/Q34530205

about

Treatment of obesity and diabetes using oxytocin or analogs in patients and mouse models.Dysregulation of glucose metabolism in HIV patients: epidemiology, mechanisms, and management.Caudal brainstem processing is sufficient for behavioral, sympathetic, and parasympathetic responses driven by peripheral and hindbrain glucagon-like-peptide-1 receptor stimulation.The incretin hormone glucagon-like peptide 1 increases mitral cell excitability by decreasing conductance of a voltage-dependent potassium channel.A New Horizon: Oxytocin as a Novel Therapeutic Option for Obesity and Diabetes The nucleus tractus solitarius: a portal for visceral afferent signal processing, energy status assessment and integration of their combined effects on food intake.Acute effects of an oral supplement of (-)-epicatechin on postprandial fat and carbohydrate metabolism in normal and overweight subjects.Progress in structure based drug design for G protein-coupled receptors.Glucagon-like peptide-1 activates endothelial nitric oxide synthase in human umbilical vein endothelial cells.Hypoglycemic effect of Chlorella vulgaris intake in type 2 diabetic Goto-Kakizaki and normal Wistar rats.Exendin-4 attenuates neuronal death via GLP-1R/PI3K/Akt pathway in early brain injury after subarachnoid hemorrhage in rats.Pharmacokinetics and Preliminary Pharmacodynamics of Single- and Multiple-dose Lyophilized Recombinant Glucagon-like Peptide-1 Receptor Agonist (rE-4) in Chinese Patients with Type 2 Diabetes Mellitus.Positron emission tomography imaging of the glucagon-like peptide-1 receptor in healthy and streptozotocin-induced diabetic pigs.

P2860

Q34734936-CE0B0259-7231-4184-9F77-1117E2440F67 Q36158019-2348A00D-BC1D-4534-BB90-E3A1F0BFB8A7 Q36796571-8A0462BE-5F10-4C85-8672-736F55FA9875 Q36897100-82D29521-B839-4022-A657-77338488B921 Q37245077-CDB1741F-0C83-4256-9800-AC029BB08AE1 Q37442573-B002FE2B-4AE6-4E0A-9C21-34272F9E8660 Q37627163-EF94EA18-FDD4-43EB-A99D-8896862CC2FB Q37880053-6CAC4F56-34A1-4EAA-B59A-F566A0A7C128 Q39234083-BFEA97B4-C8C4-46CC-86E5-F62D8B74A4F9 Q42557992-34D33EBD-F55E-4356-B3F7-91192B7EC7C5 Q48030353-64256F04-86ED-4B41-A0FB-D05CF82B2577 Q49971015-1D488746-6209-409B-B004-A281E96D2425 Q53074520-6A3CC7B3-6800-4D6F-A25D-446250EE9A26

P2860

Exenatide: a GLP-1 receptor agonist as novel therapy for Type 2 diabetes mellitus.

http://www.wikidata.org/entity/Q34530205

description

2006 nî lūn-bûn

@nan

2006 թուականի Յունիսին հրատարակուած գիտական յօդուած

@hyw

2006 թվականի հունիսին հրատարակված գիտական հոդված

@hy

2006年の論文

@ja

2006年論文

@yue

2006年論文

@zh-hant

2006年論文

@zh-hk

2006年論文

@zh-mo

2006年論文

@zh-tw

2006年论文

@wuu

name

Exenatide: a GLP-1 receptor agonist as novel therapy for Type 2 diabetes mellitus.

@ast

Exenatide: a GLP-1 receptor agonist as novel therapy for Type 2 diabetes mellitus.

@en

Exenatide: a GLP-1 receptor agonist as novel therapy for Type 2 diabetes mellitus.

@nl

type

label

Exenatide: a GLP-1 receptor agonist as novel therapy for Type 2 diabetes mellitus.

@ast

Exenatide: a GLP-1 receptor agonist as novel therapy for Type 2 diabetes mellitus.

@en

Exenatide: a GLP-1 receptor agonist as novel therapy for Type 2 diabetes mellitus.

@nl

prefLabel

Exenatide: a GLP-1 receptor agonist as novel therapy for Type 2 diabetes mellitus.

@ast

Exenatide: a GLP-1 receptor agonist as novel therapy for Type 2 diabetes mellitus.

@en

Exenatide: a GLP-1 receptor agonist as novel therapy for Type 2 diabetes mellitus.

@nl

P1433

Q34530205-F22F7AE3-FFF0-4A26-94C1-7961D63EF46D

P1476

Q34530205-1618BEA7-37D5-48CD-94B9-F26C26D6C853

P2093

Q34530205-7C230E49-3F8A-4B49-AF95-564E7425C4E7

Q34530205-A6C6DC6C-ADC4-474F-B29C-969B6CA0F4DC

P2860

Q34530205-0163A68C-3BDC-4B44-B0B6-46D3595254EE

Q34530205-05697C74-BAE0-444D-8077-5B2DC39DD3A0

Q34530205-08FE8B4D-2096-46F1-830F-9DA61A319E0E

Q34530205-10B5866C-7162-4F0E-9CD5-6F617C26161F

Q34530205-11544F98-DC74-4FE7-AC61-0C6316AB02D6

Q34530205-1659EF42-F3EB-459E-AB08-CC43C0AAC3A3

Q34530205-1661CBE6-4B19-4C9E-97C7-6E7BA79B54BE

Q34530205-1C90734A-FD3D-4B0F-9E4F-03EDE2F7C33F

Q34530205-1E0036D0-3ED3-45E0-B201-926628728C69

Q34530205-2AB0793E-CD32-444C-9E9F-82C4DC587808

P304

Q34530205-F5112F48-78DB-42BA-A4DC-0FBCDEB96392

P31

Q34530205-B496EC8D-DCCD-412C-B663-71AE200E1A5B

Q34530205-ec5d3f5a-ac9f-4f64-8bbb-8524ce01c4f4

P356

Q34530205-6E9F1461-2065-4027-9F90-5B143F8C5F54

P407

Q34530205-BEEA4415-85AD-422E-89C7-09C244F4847F

P433

Q34530205-5FBC195F-D509-4923-8EF2-FDBA76EBF603

P478

Q34530205-DF4E2BDE-F944-4098-8D3A-97853F69CDE3

P577

Q34530205-A4DE49A7-3A5A-4F87-A579-515D28971F57

P5875

Q34530205-E0F4C059-8648-4598-BE93-D119C2F19587

P698

Q34530205-0383FBE6-86ED-48A9-A787-53F872051062

P921

Q34530205-09079644-BB92-4E6F-971B-027CAF45552D

P356

14656566.7.8.1055

P1433

Expert Opinion on Pharmacotherapy

P1476

Exenatide: a GLP-1 receptor agonist as novel therapy for Type 2 diabetes mellitus.

@en

P2093

Mandeep Bajaj

http://www.w3.org/2001/XMLSchema#string

Mariele Briones

http://www.w3.org/2001/XMLSchema#string

P2860

Expression cloning of the pancreatic beta cell receptor for the gluco-incretin hormone glucagon-like peptide 1

Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). UK Prospective Diabetes Study (UKPDS) Group

Dipeptidyl-peptidase IV hydrolyses gastric inhibitory polypeptide, glucagon-like peptide-1(7-36)amide, peptide histidine methionine and is responsible for their degradation in human serum

Determinants of the effectiveness of glucagon-like peptide-1 in type 2 diabetes

Glucagon-like peptide-1 receptor signaling modulates beta cell apoptosis

Exendin-4 stimulates both beta-cell replication and neogenesis, resulting in increased beta-cell mass and improved glucose tolerance in diabetic rats

Structure-Function of the Glucagon Receptor Family of G Protein-Coupled Receptors: The Glucagon, GIP, GLP-1, and GLP-2 Receptors

Minireview: the glucagon-like peptides.

Clinical review 102: Type 2 diabetes mellitus: update on diagnosis, pathophysiology, and treatment.

The natural history of insulin secretory dysfunction and insulin resistance in the pathogenesis of type 2 diabetes mellitus.

P304

1055-1064

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1517/14656566.7.8.1055

http://www.w3.org/2001/XMLSchema#string

P407

P433

8

http://www.w3.org/2001/XMLSchema#string

P478

7

http://www.w3.org/2001/XMLSchema#string

P577

2006-06-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

7059648

http://www.w3.org/2001/XMLSchema#string

P698

16722815

http://www.w3.org/2001/XMLSchema#string

P921

type-2 diabetes